Literature DB >> 2338111

Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.

W Schneider1, G Menke, R Heidemann, P Satter, M Kaltenbach, N Rietbrock.   

Abstract

The concentrations of isosorbide dinitrate (ISDN), isosorbide-5-mononitrate (IS-5-MN) and isosorbide-2-mononitrate (IS-2-MN) were determined in plasma (PL), saphenous vein wall (SV) and pectoral muscle (PM) from 8 patients undergoing coronary bypass surgery. The patients were pretreated for 2 days with ISDN 240 mg per day (standard release formulation) in 4 doses of 40 mg and one dose of 80 mg. The plasma and tissue samples were obtained during the operation, 10-12 h after the last dose. Isosorbide-2-mononitrate and isosorbide-5-mononitrate were present in plasma and tissues in the same concentration ranges with molar concentration ratios of 0.88 (IS-2-MN: PM/PL), 0.85 (IS-5-MN: PM/PL), 0.99 (IS-2-MN: SV/PL) and 1.06 (IS-5-MN: SV/PL). Mean ISDN concentrations in tissue were considerably higher than in plasma; the molar concentration ratios were 4.9 (SM/PL) and 7.21 (SV/PL). The accumulation of ISDN in vessel walls may contribute to its greater vascular action compared to the mononitrates, but it may also facilitate the development of tolerance during long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338111     DOI: 10.1007/bf00265973

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Blood and tissue levels of [14C]isosorbide dinitrate after oral and intravenous administration to rat.

Authors:  D E Reed; J M Akester; J F Prather; J R Tuckosh; D H McCurdy; C Yeh
Journal:  J Pharmacol Exp Ther       Date:  1977-07       Impact factor: 4.030

2.  Isosorbide dinitrate pharmacokinetics.

Authors:  T Taylor; L F Chasseaud; E Doyle; R Bonn; A Darragh; R F Lambe
Journal:  Arzneimittelforschung       Date:  1982

3.  Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris.

Authors:  H L Fung; J O Parker
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

4.  Isosorbide dinitrate: pharmacokinetics after intravenous administration.

Authors:  R A Morrison; H L Fung; D Höhmann; T Meinertz; E Jähnchen
Journal:  J Pharm Sci       Date:  1982-06       Impact factor: 3.534

5.  Blood vessel uptake and metabolism of organic nitrates in the rat.

Authors:  H L Fung; S C Sutton; A Kamiya
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

6.  [Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].

Authors:  A Frydman; J Levenson; A Simon; M Safar; A Bieder; J Bertharion; J Gaillot
Journal:  Nouv Presse Med       Date:  1982-06-10

7.  [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].

Authors:  N Rietbrock; J Knoll; P G Merz; G Menke
Journal:  Dtsch Med Wochenschr       Date:  1985-11-22       Impact factor: 0.628

8.  Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood.

Authors:  B M Bennett; D A Twiddy; J A Moffat; P W Armstrong; G S Marks
Journal:  Biochem Pharmacol       Date:  1983-12-15       Impact factor: 5.858

9.  Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects.

Authors:  E F McNiff; A Yacobi; F M Young-Chang; L H Golden; A Goldfarb; H L Fung
Journal:  J Pharm Sci       Date:  1981-09       Impact factor: 3.534

10.  Pharmacokinetics of intravenous isosorbide-dinitrate.

Authors:  R Platzer; G Reutemann; R L Galeazzi
Journal:  J Pharmacokinet Biopharm       Date:  1982-12
View more
  3 in total

Review 1.  Clinical pharmacokinetics of nitrates.

Authors:  M G Bogaert
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

2.  Pharmacodynamic modeling of the in vitro vasodilating effects of organic mononitrates.

Authors:  T B Tzeng; H L Fung
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

3.  Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.

Authors:  Omar Mohamed E Abdel Salam; Amany A Sleem; Nermeen Shafee
Journal:  Inflammopharmacology       Date:  2010-01-14       Impact factor: 4.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.